Global Cell Freezing Media Market Size study & Forecast, by Product (DMSO, Glycerol) by Application (Stem Cell lines, Cancer Cell Lines, Others), by End Use (Pharmaceutical and Biotechnological Companies, Research & Academic Institutes, Others), and Regio

Global Cell Freezing Media Market Size study & Forecast, by Product (DMSO, Glycerol) by Application (Stem Cell lines, Cancer Cell Lines, Others), by End Use (Pharmaceutical and Biotechnological Companies, Research & Academic Institutes, Others), and Regional Analysis, 2023-2030

Global Cell Freezing Media Market is valued approximately at USD 140.1 million in 2022 and is anticipated to grow with a healthy growth rate of more than 9.62% over the forecast period 2023-2030. The Cell Freezing Media Market refers to biotechnology industry that focuses on the production, distribution, and utilization of specialized solutions and media used for the cryopreservation and freezing of cells to maintain their viability and functionality for future use in research, diagnostics, and therapeutic applications. The Cell Freezing Media Market is driven by factors such as growing prevalence of chronic diseases & genetic disorders and increasing R&D spending by biopharmaceutical and biotechnology companies.

Chronic diseases are characterized by long-term health conditions that require ongoing management and care. These diseases include conditions like cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders. As the incidence and prevalence of chronic diseases increase, there is a growing need for research, drug development, and therapeutic interventions to address these conditions. Increasing prevalence of chronic diseases such as diabetes is driving the market growth. According to the World Health Organization, diabetes afflicted 537 million adults globally in 2021, with one in ten experiencing other diabetes. Furthermore, according to International Diabetes Federation, The total number of people living with diabetes is projected to rise to 643 million by year 2030 and 783 million by year 2045. Along with this, there is also investment in research and development of cell freezing media is fueling the market growth. For instance, In November 2021, Sartorius made a significant investment of approximately USD 31.6 million (EUR 30 million) and inaugurated a state-of-the-art Cell Culture Technology Center spanning 65,000 square feet in Ulm, Germany, with the aim of advancing cell line development and enhancing the company’s cell culture media portfolio. Thus, increasing prevalence of chronic disease and increasing investment in R&D of cell freezing media fueling the growth of the market. In addition to advancements in cryopreservation techniques & bio preservation technologies and increasing demand for cell-based therapies create lucrative opportunities for the market. However, the High cost associated with cryopreservation and cell freezing media hinders the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cell Freezing Media Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of advanced healthcare infrastructure, developed economies, presence of key players and established supply channels. Asia Pacific is considered as the fastest growing region during the forecasted period due to growing awareness and adoption of Cell-Based Therapies and growing investments in life sciences and biotechnology

Major market player included in this report are:
Thermo Fisher Scientific, Inc.
Merck KGaA
Sartorius AG
BioLife Solutions, Inc.
HiMedia Laboratories
PromoCell GmbH,
Capricorn Scientific
Cell Applications, Inc.
STEMCELL Technologies.
BPS Bioscience, Inc.

Recent Developments in the Market:
 In March 2023, The strategic collaboration between Nucleus Biologics, Center for Breakthrough Medicines, and Stoic Bio aims to ensure a consistent supply of high-quality cellular culture medium, fostering the development of cell and gene therapies and expected to drive market growth in the future.
 In May 2022, the Kerry Group and ValitaCell established a partnership with NIBRT (National Institute of Bioprocessing Research and Training) to improve the knowledge and validation of cell culture medium products for the Kerry Group. For simulating the biological environment at the microscale, ValitaCell will offer its Chemstress platform. To encourage innovation, Enterprise Ireland provided funds for this project.

Global Cell Freezing Media Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, Application, End Use, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
DMSO
Glycerol

By Application:
Stem Cell lines
Cancer Cell Lines
Others

By End Use:
Pharmaceutical and Biotechnological Companies
Research & Academic Institutes
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Thermo Fisher Scientific, Inc.
Merck KGaA
Sartorius AG
BioLife Solutions, Inc.
HiMedia Laboratories
PromoCell GmbH,
Capricorn Scientific
Cell Applications, Inc.
STEMCELL Technologies.
BPS Bioscience, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.